Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.

Salagierski M, Schalken JA.

J Urol. 2012 Mar;187(3):795-801. doi: 10.1016/j.juro.2011.10.133. Epub 2012 Jan 15. Review.

PMID:
22245323
2.

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM.

Cancer Cell. 2010 May 18;17(5):443-54. doi: 10.1016/j.ccr.2010.03.018.

3.

Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.

Börno ST, Fischer A, Kerick M, Fälth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Röhr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sültmann H, Lehrach H, Schweiger MR.

Cancer Discov. 2012 Nov;2(11):1024-35. doi: 10.1158/2159-8290.CD-12-0041. Epub 2012 Aug 28.

4.

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM.

Sci Transl Med. 2011 Aug 3;3(94):94ra72. doi: 10.1126/scitranslmed.3001970.

5.

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1497-509. doi: 10.1158/1055-9965.EPI-12-0042. Epub 2012 Jun 26.

6.

Oncogenic activation of ERG: A predominant mechanism in prostate cancer.

Sreenath TL, Dobi A, Petrovics G, Srivastava S.

J Carcinog. 2011;10:37. doi: 10.4103/1477-3163.91122. Epub 2011 Dec 31.

7.

TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.

Am J Surg Pathol. 2007 Jun;31(6):882-8.

PMID:
17527075
8.

Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.

Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, Bapat B, van der Kwast T.

Clin Cancer Res. 2012 May 15;18(10):2896-904. doi: 10.1158/1078-0432.CCR-11-2901. Epub 2012 Mar 27.

9.

Antibody-based detection of ERG rearrangement-positive prostate cancer.

Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA.

Neoplasia. 2010 Jul;12(7):590-8.

10.

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.

Brase JC, Johannes M, Mannsperger H, Fälth M, Metzger J, Kacprzyk LA, Andrasiuk T, Gade S, Meister M, Sirma H, Sauter G, Simon R, Schlomm T, Beissbarth T, Korf U, Kuner R, Sültmann H.

BMC Cancer. 2011 Dec 5;11:507. doi: 10.1186/1471-2407-11-507.

11.

Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.

Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T.

Am J Pathol. 2012 Aug;181(2):401-12. doi: 10.1016/j.ajpath.2012.04.026. Epub 2012 Jun 13.

PMID:
22705054
12.

Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.

Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA.

Histopathology. 2012 Mar;60(4):645-52. doi: 10.1111/j.1365-2559.2011.04116.x. Epub 2012 Jan 19.

PMID:
22260502
13.

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS.

Cancer Res. 2009 Apr 1;69(7):2912-8. doi: 10.1158/0008-5472.CAN-08-3667.

14.

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP.

Nat Genet. 2009 May;41(5):619-24. doi: 10.1038/ng.370. Epub 2009 Apr 26.

15.

TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model.

Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R.

PLoS One. 2011;6(7):e21650. doi: 10.1371/journal.pone.0021650. Epub 2011 Jul 1.

16.

Whole-transcriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer.

Chow A, Amemiya Y, Sugar L, Nam R, Seth A.

Anticancer Res. 2012 Sep;32(9):3629-41.

PMID:
22993300
17.

Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models.

Becker-Santos DD, Guo Y, Ghaffari M, Vickers ED, Lehman M, Altamirano-Dimas M, Oloumi A, Furukawa J, Sharma M, Wang Y, Dedhar S, Cox ME.

Carcinogenesis. 2012 Dec;33(12):2558-67. doi: 10.1093/carcin/bgs285. Epub 2012 Oct 1.

18.

Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.

Dhani NC, Emmenegger U, Adams L, Jongstra J, Tannock IF, Sridhar SS, Knox JJ, Day JR, Groskopf J, Joshua AM.

BJU Int. 2012 Sep;110(6):840-5. doi: 10.1111/j.1464-410X.2011.10922.x. Epub 2012 Feb 7.

19.

Clinical potential of the ERG oncoprotein in prostate cancer.

Rosen P, Sesterhenn IA, Brassell SA, McLeod DG, Srivastava S, Dobi A.

Nat Rev Urol. 2012 Feb 14;9(3):131-7. doi: 10.1038/nrurol.2012.10. Review.

PMID:
22331093
20.

Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.

Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.

Prostate. 2013 Feb 15;73(3):242-9. doi: 10.1002/pros.22563. Epub 2012 Jul 20.

PMID:
22821767

Supplemental Content

Support Center